HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

ASCO 2018: Dr. Westin Sheds Light on PARP Inhibitor Abstracts in Ovarian Cancer

June 2nd 2018

ASCO 2018: Dr. Birrer on Practice-Changing Ovarian Cancer Studies

June 2nd 2018

ASCO 2018: Dr. Bekaii-Saab Highlights Pancreatic Cancer Abstracts

June 2nd 2018

ASCO 2018: Dr. Coleman Shares Insight on Ongoing Research in Ovarian Cancer

June 2nd 2018

ASCO 2018: Dr. Weber Highlights Exciting Abstracts in Melanoma

June 2nd 2018

ASCO 2018: Dr. Lonial Highlights CAR T-Cell Therapy and More in Myeloma

June 2nd 2018

ASCO 2018: Dr. Burris Highlights TAILORx and More in Breast Cancer

June 2nd 2018

ASCO 2018: Dr. Esteva Highlights CDK4/6 Inhibitors and More in Breast Cancer

June 2nd 2018

ASCO 2018: Dr. Borghaei Highlights Immunotherapy Findings in Lung Cancer

June 2nd 2018

Practice Changes for Use of Immunotherapy in NSCLC

June 2nd 2018

OncLive News Network On Location: In Chicago Monday, June 4

June 2nd 2018

OncLive News Network On Location: In Chicago Sunday, June 3

June 2nd 2018

OncLive News Network On Location: In Chicago Saturday, June 2

June 2nd 2018

OncLive News Network On Location: In Chicago Friday, June 1

June 2nd 2018

Dr. Mitri Discusses Adjuvant Therapy for HER2+ Breast Cancer

May 31st 2018

Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses adjuvant therapy for patients with HER2-postive breast cancer.

Expert Recaps Adjuvant Advancements in HER2+ Breast Cancer

May 24th 2018

Haythem Y. Ali, MD, discusses adjuvant advances in HER2-postitive breast cancer and emerging agents in the field.

Dr. Pegram Discusses the Use of Neratinib in HER2+ Breast Cancer

May 23rd 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the use of neratinib (Nerlynx) in the treatment of patients with HER2-positive breast cancer.

Dr. Ali on Choosing Adjuvant Treatment for HER2+ Breast Cancer

May 18th 2018

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses the adjuvant treatment of patients with HER2-positive breast cancer.

Shorter Trastuzumab Duration Matches 12-Month Standard for Early HER2+ Breast Cancer

May 17th 2018

A shorter 6-month course of adjuvant trastuzumab (Herceptin) was found to be noninferior for disease-free survival compared with the standard 12-month schedule for patients with HER2-positive early breast cancer.

Dr. Verma on Immunotherapy in HER2+ Breast Cancer

May 14th 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses immunotherapy in HER2-positive breast cancer.